Ameriprise
RAPP

Ameriprise’s Rapport Therapeutics RAPP Stock Holding History

Ameriprise’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$456K Sell
14,585
-209
-1% -$5.88K ﹤0.01% 3624
2025
Q4 		$449K Sell
14,794
-110,009
-88% -$3.04M ﹤0.01% 3666
2025
Q3 		$3.71M Buy
+124,803
New +$2.23M ﹤0.01% 2641

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Ameriprise's RAPP Position: Q1 2026 in Review

Ameriprise reduced its Rapport Therapeutics (RAPP) stake by 1.4% in Q1 2026, selling an estimated $5.88K and leaving 14,585 shares worth $456K. The position accounts for ﹤0.01% of the portfolio, ranked #3624.

Ameriprise first reported a position in RAPP in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.71M in Q3 2025. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Ameriprise held 14,585 shares of Rapport Therapeutics worth $456K as of Q1 2026.
  • Ameriprise sold 209 Rapport Therapeutics shares in Q1 2026, an estimated $5.88K.
  • Rapport Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3624 holding.
  • Ameriprise first reported a position in Rapport Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Ameriprise's Rapport Therapeutics position peaked at $3.71M in Q3 2025.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.